Pharmacogenetic analysis of TS and UGT1A polymorphisms predictive for response and toxicity in Spanish patients with advanced colorectal cancer treated with first-line irinotecan and 5-fluorouracil

被引：0
|
作者：
Martinez-Balibrea, E. [1 ,2 ,3 ,4 ,5 ,6 ]
Abad, A. [1 ,2 ,3 ,4 ,5 ,6 ]
Valladares, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Martinez-Villacampa, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Aranda, E. [1 ,2 ,3 ,4 ,5 ,6 ]
Marcuello, E. [1 ,2 ,3 ,4 ,5 ,6 ]
Benavides, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Martinez-Cardus, A. [1 ,2 ,3 ,4 ,5 ,6 ]
Gines, A. [1 ,2 ,3 ,4 ,5 ,6 ]
Manzano, J. L. [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain
[2] Hosp Juan Canalejo, La Coruna, Spain
[3] Hosp Duran & Reynals, ICO, Lhospitalet De Llobregat, Spain
[4] Hosp Reina Sofia, Cordoba, Spain
[5] Hosp Sant Pau, Barcelona, Spain
[6] Hosp Carlos Haya, Malaga, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4066
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Predictive role of a pharmacogenetic profiling in patients with advanced colorectal cancer (ACRC) treated with first-line, 5-fluorouracil/irinotecan chemotherapy
    Ruzzo, A. M.
    Catalano, V
    Bisonni, R.
    Loupakis, F.
    Canestrari, E.
    Santini, D.
    Ficarelli, R.
    Mari, D.
    Maltese, P.
    Schiavon, G.
    Pizzagalli, F.
    Masi, G.
    Safina, V
    Giordani, P.
    Lippe, P.
    Alessandroni, P.
    Giustini, L.
    Falcone, A.
    Tonini, G.
    Silva, R. R.
    Mattioli, R.
    Menichetti, E. T.
    Testa, E.
    Lai, V
    Magnani, M.
    Graziano, F.
    ANNALS OF ONCOLOGY, 2006, 17 : XI41 - XI42
  • [2] UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy
    Martinez-Balibrea, E.
    Abad, A.
    Martinez-Cardus, A.
    Gines, A.
    Valladares, M.
    Navarro, M.
    Aranda, E.
    Marcuello, E.
    Benavides, M.
    Massuti, B.
    Carrato, A.
    Layos, L.
    Manzano, J. L.
    Moreno, V.
    BRITISH JOURNAL OF CANCER, 2010, 103 (04) : 581 - 589
  • [3] UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy
    E Martinez-Balibrea
    A Abad
    A Martínez-Cardús
    A Ginés
    M Valladares
    M Navarro
    E Aranda
    E Marcuello
    M Benavides
    B Massutí
    A Carrato
    L Layos
    J L Manzano
    V Moreno
    British Journal of Cancer, 2010, 103 : 581 - 589
  • [4] Predictive role of a pharmacogenetic profiling in patients with advanced colorectal cancer (ACRC) treated with first-line, 5-fluorouracil/oxaliplatin chemotherapy
    Graziano, F.
    Ruzzo, A. M.
    Loupakis, F.
    Canestrari, E.
    Santini, D.
    Catalano, V
    Ficarelli, R.
    Mari, D.
    Bisonni, R.
    Masi, G.
    Schiavon, G.
    Safina, V
    Maltese, P.
    Pizzagalli, F.
    Giordani, P.
    Lippe, P.
    Alessandroni, P.
    Giustini, L.
    Falcone, A.
    Tonini, G.
    Silva, R. R.
    Mattioli, R.
    Menichetti, E. T.
    Testa, E.
    Lai, V
    Magnani, M.
    ANNALS OF ONCOLOGY, 2006, 17 : XI42 - XI43
  • [5] Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
    B Glimelius
    H Garmo
    Å Berglund
    L A Fredriksson
    M Berglund
    H Kohnke
    P Byström
    H Sørbye
    M Wadelius
    The Pharmacogenomics Journal, 2011, 11 : 61 - 71
  • [6] Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
    Glimelius, B.
    Garmo, H.
    Berglund, A.
    Fredriksson, L. A.
    Berglund, M.
    Kohnke, H.
    Bystrom, P.
    Sorbye, H.
    Wadelius, M.
    PHARMACOGENOMICS JOURNAL, 2011, 11 (01): : 61 - 71
  • [7] Refining the UGT1A Haplotype Associated with Irinotecan-Induced Hematological Toxicity in Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Irinotecan-Based Regimens
    Levesque, Eric
    Belanger, Anne-Sophie
    Harvey, Mario
    Couture, Felix
    Jonker, Derek
    Innocenti, Federico
    Cecchin, Erica
    Toffoli, Giuseppe
    Guillemette, Chantal
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2013, 345 (01): : 95 - 101
  • [8] Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
    Pare, L.
    Marcuello, E.
    Altes, A.
    del Rio, E.
    Sedano, L.
    Salazar, J.
    Cortes, A.
    Barnadas, A.
    Baiget, M.
    BRITISH JOURNAL OF CANCER, 2008, 99 (07) : 1050 - 1055
  • [9] Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
    L Paré
    E Marcuello
    A Altés
    E del Río
    L Sedano
    J Salazar
    A Cortés
    A Barnadas
    M Baiget
    British Journal of Cancer, 2008, 99 : 1050 - 1055
  • [10] Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer
    Ji, SH
    Park, YS
    Lee, J
    Lim, DH
    Park, BB
    Park, KW
    Kang, JH
    Lee, SH
    Park, JO
    Kim, K
    Kim, WS
    Jung, CW
    Im, YH
    Kang, WK
    Park, K
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (04) : 214 - 217
12345